Inactive Instrument

Seagen Inc.

SGEN

US81181C1045

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Seagen Inc.

Takeover rumors send Morphosys to high since July 2021	05/02	DP
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index	18/12	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index	18/12	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index	18/12	CI
Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev	16/12	DJ
Pfizer: dividend increases, stock rebounds	15/12	CF
Euphoria subsides for Triple-Witching Day	15/12
Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...	15/12
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	15/12	MT
Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index	15/12	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index	15/12	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index	15/12	CI
Pfizer, Inc: A cycle for nothing?	14/12
Pfizer Completes $43 Billion Acquisition of Seagen	14/12	MT
Pfizer: Seagen acquisition now complete	14/12	CF
Seagen Inc. Announces Management Changes	14/12	CI
Seagen Inc. Announces Cessation of David R. Epstein as Chief Executive Officer	14/12	CI
Seagen Inc. Announces Cessation of Todd E. Simpson as Chief Financial Officer	14/12	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ Composite Index	14/12	CI
Pfizer Inc. completed the acquisition of Seagen Inc. from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.	14/12	CI
Pfizer shares sink after it resets 2024 COVID expectations	14/12	RE
Sector Update: Tech Stocks Rise Late Afternoon	14/12	MT
Sector Update: Tech Stocks Mixed Wednesday Afternoon	14/12	MT
Global markets live: BAE Systems, Amazon, Take-Two, Shell, Pfizer...	13/12
Pfizer shares slide as 2024 revenue outlook underwhelms	13/12	AN

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).

Employees

3,256

Sector

Biotechnology & Medical Research

More about the company